Paul Feuerstadt, MD: The Promise of RBX2660 for C Difficile

Video

RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.

RBX2660 could make a major difference in treating recurrent Clostridioides difficile infections (rCDI).

Similar to how fecal microbiota transplantation (FMT) is a viable treatment, RBX2660 is a standardized, stabilized, investigational microbiota-based live therapeutic.

In data presented at the 2021 American College of Gastroenterology (ACG) Annual Meeting, investigators found high clinical efficacy in reducing rCDI with a sustained clinical response up to 6 months, with consistent safety results from previous clinical trials.

In the new trial, 94 patients were examined from 5 sites between November 2015 and September 2019, 64 of which were in the primary safety set with a treatment success rate of 82.8% (n = 53). There was no different between patients who received 1 dose (83.3%; n = 20) compared to 2 doses (82.5%; n = 33).

For the patients who initially responded, 88.7% ( n = 47) sustained a clinical response at 6 months.

For safety, 92.2% of the adverse events reported were deemed mild or moderate in severity, including in patients with immune-mediated or autoimmune disorders and non-specific inflammation conditions.

In an interview with HCPLive®, Paul Feuerstadt , MD, Yale University School of Medicine, explained how RBX2660 leverages new technology and why that could be an answer in treating C difficile infections.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.